Results 91 to 100 of about 2,303 (187)

Single-dose nirsevimab prevents RSV infection [PDF]

The Journal of Pediatrics, 2021
Shabir A, Madhi, Eric A F, Simões
openaire   +2 more sources

Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season

Vaccines
Respiratory syncytial virus (RSV) bronchiolitis remains a significant global health burden, particularly in newborns and infants during their first year of life.
Alessandra Consolati, Mariapaola Farinelli, Paolo Serravalle, Christine Rollandin, Laura Apprato, Susanna Esposito, Salvatore Bongiorno   +6 more
doaj   +1 more source

Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025

Respiratory syncytial virus (RSV) is a leading cause of intensive care unit (ICU) admission and respiratory failure among infants (children aged \u3c year) in the United States.
Orzel-Lockwood, Amber O., Schuster, Jennifer E., al, et, Zerr, Danielle M., Gertz, Shira J., Irby, Katherine, Payne, Amanda B., Calixte, Jemima M., Chiotos, Kathleen, Crandall, Hillary, Nofziger, Ryan A., Hume, Janet R., Simeone, Regina M., Kamidani, Satoshi, Shein, Steven L., Halasa, Natasha B., Maddux, Aline B., Michelson, Kelly N., Newhams, Margaret M., Bhumbra, Samina S., Chauhan, Jigar C., Guzman-Cottrill, Judith A., Coates, Bria M., Staat, Mary Allen, Kong, Michele, Martin, Lora M., Bradford, Tamara T., Cameron, Melissa A., Zambrano, Laura D.   +28 more
core   +2 more sources

The Efficacy and Safety of Nirsevimab in the Prevention of RSV Related Infections in Healthy Infants [PDF]

Objective: To assess the efficacy and safety of preventing Respiratory Syncytial virus (RSV) related respiratory illnesses and hospitalization with the use of Nirsevimab, as compared to placebo among infants among healthy early and late preterm infants ...
Mayo, Gabrielle, Ballard, Suyin
core  

Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost–utility modelling study

BMJ Public Health
Introduction Respiratory syncytial virus (RSV) causes great morbidity and mortality among newborns. Nirsevimab represents a prophylactic alternative used in Spain for a universal prophylaxis strategy of all infants.
Miguel Angel Casado, Ruth Gil-Prieto, Jaime Pérez-Martín, Ariadna Díaz Aguiló, Samira Soudani, Leticia Platero-Alonso, Juan Luis López-Belmonte, Alberto de la Cuadra-Grande, Javier Álvarez Aldean   +8 more
doaj   +1 more source

Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

Human Vaccines & Immunotherapeutics
Nirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023.
Narmeen Mallah, Sonia Ares-Gómez, Jacobo Pardo-Seco, Alberto Malvar-Pintos, María-Isolina Santiago-Pérez, Olaia Pérez-Martínez, María-Teresa Otero-Barrós, Nuria Suárez-Gaiche, Rolf Kramer, Jing Jin, Leticia Platero-Alonso, Rosa-María Alvárez-Gil, Olga-María Ces-Ozores, Victoria Nartallo-Penas, Susana Mirás-Carballal, Marta Piñeiro-Sotelo, Juan-Manuel González-Pérez, Carmen Rodríguez-Tenreiro, Irene Rivero-Calle, Antonio Salas, Carmen Durán-Parrondo, Federico Martinón-Torres   +21 more
doaj   +1 more source

Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations.

JAMA Pediatr
Importance: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants and young children, imposing a substantial burden on health care systems.
Attaianese F, Carreras G, Trapani S, Alberti I, Aricò M, Attanasi M, Bertolucci G, Bressan S, Caselli D, Casotto V, Cazzato S, Chiarelli F, Felici E, Frusciante A, Galeone MA, Garazzino S, Giannattasio A, Gitto E, Guerriero A, Guida F, Iudica G, Lanari M, Mandato C, Manzini A, Martelli G, Milani GP, Moriondo M, Notarangelo LD, Nunziata F, Pellegrino R, Peroni D, Piccotti E, Ponticiello E, Ricci S, Rulli I, Savoia F, Silvestro E, Sisto A, Soro F, Tonetto S, Zago A, Dani C, Azzari C, Indolfi G.   +43 more
europepmc   +2 more sources

Reliability of RSV Antigen Diagnostic Tests in the Presence of Nirsevimab

Pediatric Infectious Disease Journal
Background: Nirsevimab is approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Although nucleic acid detection by polymerase chain reaction is primarily utilized for the clinical diagnosis of RSV, antigen detection is still routinely used and ...
Sarah R. Sincero, Kelly Ann Mahool, Emma Schaefer, Carolina S. Caceres, Elizabeth J. Kelly, Deidre Wilkins, Kevin M. Tuffy   +6 more
openaire   +2 more sources

Changes in Respiratory Syncytial Virus‐Associated Hospitalisations Epidemiology After Nirsevimab Introduction in Lyon, France

International audienceBackground Respiratory Syncytial Virus (RSV) is a major health concern, particularly for infants. In France, Nirsevimab, a long‐acting monoclonal antibody to prevent RSV‐associated lower respiratory tract infections (LRTI) was ...
Ploin, Dominique, Butin, Marine, Horvat, Côme, Javouhey, Etienne, Hassenboehler, Juliette, Casalegno, Jean‐sebastien, Gillet, Yves, Plaisant, Franck, Ragouilliaux, Corinne, Nunes, Marta C., Chauvel, Cécile, Chakra, Claire Nour Abou   +11 more
core   +1 more source

Analysis of Beyfortus^® (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention

Current Issues in Molecular Biology
Respiratory infections with respiratory syncytial virus (RSV) account for an important part of hospital admissions for acute respiratory infections. Nirsevimab has been developed to reduce the hospital burden of RSV infections.
Hélène Banoun
doaj   +1 more source